Why the study?
Does intravenous immunoglobulin improve clinical and biochemical outcomes in a patient with disseminated enterovirus infection on maintenance ocrelizumab?
Does intravenous immunoglobulin improve clinical and biochemical outcomes in a patient with disseminated enterovirus infection on maintenance ocrelizumab?
Intravenous immunoglobulin may be an effective treatment for disseminated enterovirus infection in patients receiving ocrelizumab for multiple sclerosis.
Ocrelizumab may predispose to severe enterovirus in MS; leaves open incidence, causality, and surveillance needs.
We present a case of a woman in her 40s with disseminated enterovirus infection in the setting of maintenance therapy with ocrelizumab for relapsing-remitting multiple sclerosis. The patient originally presented with fever, bilateral lower limb swelling and hypoalbuminaemia. She subsequently developed a productive cough and diarrhoea, and a viral respiratory multiplex panel detected rhino/enterovirus. Despite supportive care, the patient continued to deteriorate with persistent high-grade fevers and progressive derangement of her liver biochemistry. Repeat viral respiratory multiplex testing failed to detect rhino/enterovirus and, therefore, she was investigated for a fever of unknown origin. However, initial extensive special investigations identified no alternate infective, inflammatory or malignant cause. On further testing, enterovirus RNA was detected by specific monoplex nucleic acid amplification test (NAAT) in whole blood, stool and from a targeted enterovirus nasopharyngeal swab. The patient was eventually treated with intravenous immunoglobulin, which led to marked clinical and biochemical improvement.
No takes yet. Share an insight, caveat, or question.
Nel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: